A prescription appears to end with a straightforward transaction: a clinician writes it, a patient visits a pharmacy, and the medicine is dispensed. Yet the price a patient encounters can vary by pharmacy, insurance status, benefit design, discount network, and negotiated rate. The same medicine may carry several possible prices that are difficult to see before reaching the counter.
GoodRx, founded in 2011 by technology executives including Trevor Bezdek and Doug Hirsch, approached that opacity as an information problem. Its consumer product gathered geographically relevant prescription prices and presented them through a searchable interface. A user could compare options and obtain a GoodRx code for a negotiated price at a participating pharmacy.
The value to the consumer was visible: greater certainty and, in many cases, a lower cash price. The business underneath was less intuitive. The consumer did not pay GoodRx to search.
Follow the transaction
When a consumer used a GoodRx code to fill a prescription, GoodRx received fees from partners, primarily pharmacy benefit managers. PBMs helped establish and process the negotiated transactions. Pharmacies accepted the codes in exchange for the opportunity to fill prescriptions and gain customer traffic. GoodRx brought consumer demand into the network.
The result was a multi-sided business. The beneficiary, payer, distributor, and access controller were not the same party. The free comparison experience could grow because another set of stakeholders funded the transaction.
GoodRx’s 2020 public filing showed both the strength and the dependency of the model. Prescription transaction fees produced approximately 94 percent of 2019 revenue. More than 80 percent of prescription transactions since 2016 came from repeat activity. A code saved in a pharmacy profile could continue applying to refills, creating repeated use without the consumer repeating the entire search.
But the company also depended heavily on PBM relationships, participating pharmacies, and prices it did not fully control. Its filings warned that changes in partner arrangements, pharmacy participation, regulation, prescription prices, or consumer behavior could affect the offering and its economics. The simple consumer surface was supported by negotiated access to a complex system.
Price transparency can help an individual without changing why the underlying system produces opaque or variable prices. GoodRx reduced search friction and made existing discount pathways easier to use. That is meaningful. It is also different from redesigning the pharmaceutical pricing system itself.
The strategic lesson travels beyond prescriptions. When a product is free to the user, its real architecture may be hidden. Understanding the business requires tracing the transaction: who benefits, who pays, who grants access, what behavior changes, and where dependency accumulates.
Sources and further reading
Keep exploring
23andMe: What happens to trust when the company changes hands?Bright Health: When does integration add more complexity than control?Put the question to work with an AI prompt →Browse all cases →For a discussion tailored to your team, explore a workshop with Julien.